TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34582451
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (blended corn/soy flour and intermittent preventive treatment for malaria in pregnancy)
Study: 32216723
Drug: 10% Carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Carbamide gel
Study: 32216723
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide gel
Study: 33556381
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVT‐AFL) 2 mg at baseline and every 4 weeks thereafter
Study: 35745116
Drug: Low-Carbohydrate Oral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Carbohydrate Oral Nutritional Supplement (LC-ONS)
Study: 35745116
Drug: Standard Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Oral Nutritional Supplement (ST-ONS)
Study: 33399934
Drug: novel adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA
Study: 32783912
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) for peanut allergies
Study: 33183969
Drug: Symptom-palliating treatment
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-palliating treatment
Study: 33183969
Drug: Guideline-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based treatments or guideline-based treatments in combination with non-guideline-based treatments
Study: 33183969
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (guideline based or non-guideline based)
Study: 32645162
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) regimens including nucleoside/nucleotide reverse‐transcriptase inhibitor (NRTI) plus nonnucleoside reverse‐transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%).
Study: 34490707
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg once daily
Study: 34490707
Drug: Clofazimine 100
Normalized name: clofazimine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 100 mg thrice daily
Study: 36403976
Drug: Low-dose febuxostat
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose febuxostat (20 mg/day)
Study: 36403976
Drug: Allopurinol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (200 mg/day)
Study: 36403976
Drug: Low-dose febuxostat
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose febuxostat
Study: 33449480
Drug: Promethazine sensitization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine sensitization via oral exposure
Study: 32596393
Drug: Tripterygium glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium glycosides from Tripterygium wilfordii Hook F (TwHF) combined with angiotensin receptor blocker (ARB)
Study: 32596393
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blocker (ARB) only
Study: 35899486
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with topical irradiated amniotic collagen matrix (IACM)
Study: 35899486
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with topical platelet rich plasma (PRP)
Study: 32000167
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Study: 32000167
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Study: 32050061
Drug: Polymer-free drug-coated
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer-free drug-coated stents
Study: 32829105
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation
Study: 32829105
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of irinotecan based on UGT1A1 genotyping
Study: 33840246
Drug: Subcutaneous tunneling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous tunneling technique
Study: 33388289
Drug: Pre-hospital tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital tirofiban administration
Study: 33057314
Drug: IV2 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV2 (two intravenous doses of 15 mg TXA/kg: prior to skin incision and 6 hours after the first dose)
Study: 33057314
Drug: TOP (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP (2 g TXA in 50 mL of saline irrigated topically at the end of the surgery)
Study: 35429481
Drug: Night-time subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time subcutaneous apomorphine infusion (up to 5 mg/h)
Study: 35429481
Drug: Night-time subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time subcutaneous apomorphine infusion
Study: 33067919
Drug: Low-dose mindfulness-based
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose mindfulness-based intervention (MBI) - weekly 1-hour mindfulness training over 4 weeks
Study: 35616850
Drug: Thymosin α1
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin α1 (Tα1) treatment
Study: 35300599
Drug: Patient-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-initiated treatment model for HFS and BEB using botulinum toxin type A (BoNT/A) with self-determined treatment schedule for 9 months.
Study: 35300599
Drug: Patient-initiated treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-initiated treatment model for HFS and BEB.
Study: 33633036
Drug: DOR/3TC/TDF (once-daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOR/3TC/TDF (once-daily)
Study: 35014061
Drug: BAY 2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 2433334 (25/50/100 mg once daily)
Study: 35014061
Drug: BAY 2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 2433334 (25 mg twice daily)
Study: 35014061
Drug: BAY 2433334
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 2433334 (75 mg once daily)
Study: 32852548
Drug: Open-loop therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-loop therapy (OL)
Study: 36910347
Drug: Drotaverine hydrochloride
Normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine hydrochloride (40mg, 2 ml intravenous)
Study: 36910347
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml Vitamin B complex)
Study: 33980033
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin Type A (BTX‐A) injection
Study: 33618395
Drug: Early stage
Normalized name: SALICYLIC ACID 0.14 mg TOPICAL PATCH [Peace Out Early Stage Acne Dot]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early stage periarticular injection
Study: 33618395
Drug: Late stage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late stage periarticular injection
Study: 33200439
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education (OHE), toothbrushes, fluoride toothpaste, and fluoride varnish on up to six occasions
Study: 36360757
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation (4-month daily micronutrient packets)
Study: 33755846
Drug: Vasopressor administration
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressor administration (phenylephrine and noradrenaline)
Study: 32940745
Drug: Interdisciplinary multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary multimodal assessment by pain medicine specialists, physiotherapists, and clinical psychologists.
Study: 33746023
Drug: Ranibizumab (intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (intravitreal anti-VEGF agents)
Study: 32780999
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human antithrombin 250 mg loading dose followed by continuous infusion of 2000 mg per 24 hours
Study: 32780999
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical saline infusion)
Study: 35801003
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPIs) and H2 blockers
Study: 34836236
Drug: Peanut Protein
Normalized name: peanut protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut Protein Supplementation (PP; 75 total g/d of powder providing 30 g/d protein, >9.2 g/d essential amino acids, 315 kcal/d)
Study: 34836236
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-supplement group; CTL; n = 16 females, n = 8 males)
Study: 33368960
Drug: LY2140112 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2140112 (LY) 100 mg
Study: 33368960
Drug: LY2140112 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2140112 (LY) 130 mg
Study: 33368960
Drug: LY2140112 (LY)
Normalized name: LYS
DrugBank: Lysine (DB00123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LY2140112 (LY) 5-75 mg
Study: 36498818
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group not specified, but implied as standard treatment or placebo.
Study: 32326806
Drug: GLP-1RA +
Normalized name: IL-1RA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GLP-1RA + SGLT-2i (combination therapy)
Study: 32326806
Drug: Control (Insulin)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Insulin)
Study: 35490936
Drug: Vasopressin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (20 IU) and Methylprednisolone (40 mg)
Study: 34531021
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no-tablet months)
Study: 35191924
Drug: Sublingual dexmedetomidine
Normalized name: dexmedetomidine Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dexmedetomidine 180 μg
Study: 35191924
Drug: Sublingual dexmedetomidine
Normalized name: dexmedetomidine Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dexmedetomidine 120 μg
Study: 34025637
Drug: Chemotherapy-allo-HSCT
Normalized name: allo-2-hydroxycitric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-allo-HSCT
Study: 32890299
Drug: Intraoperative wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative wound infiltration with local anesthetics, morphine sulfate, epinephrine, and nonsteroidal anti-inflammatory drugs; postoperative patient-controlled analgesia (PCA).
Study: 32890299
Drug: Intraoperative wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative wound infiltration with multimodal drugs; postoperative patient-controlled analgesia (PCA).
Study: 34678128
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide at 45 μg/kg ideal body weight/h (iNO45)
Study: 32033612
Drug: Protective lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective lung ventilation (VT set at 6 ml/kg of predicted body weight with individualized PEEP during dura opening)
Study: 32033612
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (VT set at 8 ml/kg of predicted body weight, no PEEP or recruitment maneuvers)
Study: 35324339
Drug: Tapering group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering group (0.4mg/kg/day of methylprednisolone orally for 7 days, followed by progressive reduction of 8 mg per week for 3 weeks)
Study: 35289004
Drug: Occupational therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy-based intervention
Study: 35023557
Drug: Sodium Benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Benzoate (250-1500 mg/d)
Study: 35023557
Drug: Sertraline (25-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25-150 mg/d)
Study: 32537732
Drug: Matrix rhythm
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix rhythm therapy (MRT) combined with Bobath therapy (BT)
Study: 32537732
Drug: Bobath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath therapy (BT)
Study: 35509085
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral ferrous sulfate (60 mg of elemental iron) daily for 12 weeks
Study: 35509085
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral ferrous sulfate (60 mg of elemental iron) every other day for 12 weeks
Study: 35332040
Drug: HN001 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HN001 capsules
Study: 32526362
Drug: Curative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curative treatment
Study: 32526362
Drug: Active UIA
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active UIA treatment
Study: 32526362
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment or surgical treatment
Study: 32384727
Drug: Three-day bamboo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day bamboo forest therapy session
Study: 33647776
Drug: Multi-component combination
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component combination of HQD (MCHD)
Study: 33118309
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin users with continuous glucose monitoring (CGM)
Study: 34925044
Drug: Ginkgolide® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgolide® treatment with IV rt‐PA
Study: 34925044
Drug: Ginkgolide® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgolide® treatment with IV rt‐PA after propensity score matching
Study: 32948867
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (WP) combined with low-fiber (LoFi; 10 g dietary fiber/day)
Study: 32418856
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) administered intraoperatively after open arthrolysis
Study: 32418856
Drug: Saline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration (control group)
Study: 32145206
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity pulsed ultrasound (LIPUS) stimulation (1.5 MHz, 30 mW/cm2) for 20 minutes daily on postoperative days 4, 8, 14, and 20
Study: 34387520
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 60,000 IU weekly for 8 weeks
Study: 33941219
Drug: Hylan G‐F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G‐F 20
Study: 32076718
Drug: Prophylaxis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis therapy
Study: 35715946
Drug: DPP-4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitors (including sitagliptin)
Study: 34424530
Drug: Decitabine monotherapy
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine monotherapy (control arm)
Study: 34424530
Drug: Decitabine in
Normalized name: decitabine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine in alternating cycles with sapacitabine (study arm) in patients with white blood cell counts <10 × 10^9 /L
Study: 34424530
Drug: Decitabine monotherapy
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine monotherapy (control arm) in patients with white blood cell counts <10 × 10^9 /L
Study: 32786002
Drug: Benzodiazepine receptor
Normalized name: GABA-benzodiazepine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine receptor agonists (BZRAs)
Study: 34181474
Drug: Critically drug-resistant
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critically drug-resistant E. coli
Study: 34181474
Drug: Critically drug-resistant
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critically drug-resistant K. pneumoniae
Study: 34181474
Drug: Critically drug-resistant
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critically drug-resistant Acinetobacter baumannii
Study: 34181474
Drug: Critically drug-resistant
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critically drug-resistant Pseudomonas aeruginosa
Study: 32442781
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy (10 sessions)
Study: 36239914
Drug: Senaparib 100
Normalized name: Senaparib
DrugBank: Senaparib (DB17163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senaparib 100 mg in fasted state
Study: 36239914
Drug: Senaparib 100
Normalized name: Senaparib
DrugBank: Senaparib (DB17163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senaparib 100 mg in fed state
Study: 33862206
Drug: Laparoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic treatment (group 1), 13 patients, 2 required conversion to open surgery.
Study: 32979074
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Exercise Training
Study: 36266683
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (4,000 units daily for 18 weeks)
Study: 34215149
Drug: IMPULS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPULS treatment (8 weekly sessions)
Study: 34297338
Drug: Amikacin 25
Normalized name: amikacin 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 25 mg/kg intravenously
Study: 34297338
Drug: Amikacin 15
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin 15 mg/kg intravenously
Study: 34297338
Drug: Amikacin 25
Normalized name: amikacin 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 25 mg/kg and 15 mg/kg
Study: 34810217
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus endocrine therapy (ET group, n = 196)
Study: 34810217
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy (CT group, n = 196)
Study: 33085058
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus oxaliplatin 130 mg/m2 (SOX130)
Study: 34261793
Drug: Original VRC26.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original VRC26.25 antibody
Study: 32058608
Drug: Needleless administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Needleless administration of SCIT
Study: 32058608
Drug: Traditional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional administration of SCIT
Study: 35021944
Drug: Nanocurcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocurcumin (80 mg/day for 8 weeks)
Study: 36104138
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg on day 1 of the first week of each 8-week cycle, alternating with NIVO 480 mg monotherapy on day 1 of the fifth week of each 8-week cycle
Study: 36104138
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg
Study: 36154660
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral treatment for hepatitis C virus (HCV)
Study: 33158777
Drug: Intraluminal brachytherapy
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal brachytherapy using 125I seed strand and CT‐guided percutaneous radioactive seed implantation therapy
Study: 33158777
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with gemcitabine and cisplatin
Study: 32591274
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side (no L-PRF)
Study: 32507285
Drug: I-gel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel®
Study: 35841075
Drug: Ethanol‐based handrub
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol‐based handrub gel with superfatting agents (Saniswiss Sanitizer Hands H1)
Study: 35841075
Drug: Isopropanol‐based formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isopropanol‐based formulations (Hopirub® or Hopigel®)
Study: 33780276
Drug: Neoadjuvant chemohormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemohormonal therapy and radical prostatectomy